Veru Inc. VERU
Analyst Ratings
- Consensus
- Buy — 3 Buy · 0 Hold · 0 Sell (3 analysts)
- Avg. Price Target
- $25.67 (+1045.8% upside)
Key Stats
- Today's Range
- $2.22 – $2.32
- 50-Day Range
- $2.11 – $2.85
- 52-Week Range
- $2.05 – $7.33
- Volume
- 123K shs
- Average Volume
- 188K shs
- Market Cap
- $38.19 million
- P/E Ratio
- —
- Dividend Yield
- 12.50%
Dividend
- Dividend Yield
- 12.50%
- Annual Dividend
- $0.28
- Payout Ratio
- —
- Ex-Dividend Date
- 2014-04-28
Short Interest
- Short Interest
- 2.13%
- Days to Cover
- 2.78
About Veru Inc.
Veru Inc is a late clinical-stage biopharmaceutical focused on developing medicines for the treatment of cardiometabolic and inflammatory diseases. Its drug development program consists of two late-stage new chemical entities, enobosarm and sabizabulin. Enobosarm, an oral selective androgen receptor modulator, is being developed to make weight reduction by GLP-1 RA drugs more tissue selective for loss of fat and preservation of lean mass, and is planned for a Phase 2b PLATEAU clinical study in obesity. Sabizabulin, an oral microtubule disruptor, is being developed for the treatment of inflammation in atherosclerotic cardiovascular disease to lower high-sensitivity CRP in patients with stable coronary artery disease, with a planned Phase 2 study.
Related Stocks
Compare head-to-head: VERU vs LLY·VERU vs JNJ·VERU vs ABBV·VERU vs ABT
Price and fundamental data are delayed and provided for informational purposes only. Not investment advice. See our disclaimer.